Please sign in to follow a disease.
New hope for stubborn lung infection? drug trial underway
NCT ID NCT05496374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called SPR720 in 25 adults with a chronic lung infection caused by Mycobacterium avium complex (MAC). The goal was to see if the drug can reduce bacteria in sputum and is safe compared to a placebo. Participants took the drug or placebo by mouth for 8 weeks, and researchers measured changes in infection levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
25 people
The number who actually took part.
- Started
-
Dec 2022
- Finished
-
Dec 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Has a prior diagnosis of NTM-PD due to MAC according to American Thoracic Society (ATS) criteria 2. Has at least one prior lower respiratory culture (sputum or bronchoalveolar lavage \[BAL\]) positive for MAC in the 12 months prior to consent 3. Has an induced sputum culture at Screening positive for MAC by quantitative culture on solid agar 4. Is either treatment naïve and has not received any prior treatment for MAC, OR if previously treated for MAC and meets all of the following criteria: 1. Has a history of successful treatment with sputum culture conversion to negative 2. Has recent sputum or BAL culture evidence of recurrent or relapsed disease and 3. Has been off therapy for at least 3 months prior to consent 5. Has clinical signs and symptoms within the 6 weeks prior to consent that are consistent with NTM-PD with ≥2 of the following: 1. chronic cough 2. fatigue 3. frequent throat clearing 4. shortness of breath (dyspnea) 5. coughing up of blood (hemoptysis) 6. excessive mucus (sputum) production 7. fever (temperature \>38ºC or \>100.4ºF) 8. night sweats 9. loss of appetite 10. unintended weight loss 11. wheezing 12. chest pain 6. Has a measured forced expiratory volume in the first second following maximal inhalation (FEV1) % predicted ≥30% within 3 months prior to consent. If prior FEV1% predicted test result is not available, obtain FEV1% predicted at Screening to confirm eligibility Exclusion Criteria: 1. In the opinion of the Investigator, is not a candidate for a 5-month delay in initiation of standard multidrug therapy to participate in a placebo-controlled clinical trial (e.g., participant has severe symptoms or, extensive disease burden) 2. Has disseminated or extrapulmonary NTM disease 3. Has end-stage NTM-PD or treatment-refractory NTM-PD 4. Has isolation on lower respiratory (sputum or BAL) cultures of any Mycobacterium species other than those included in MAC within the 6 months prior to consent 5. Has any other condition or prior therapy, which, in the opinion of the Investigator, would make the participant unsuitable for this study, including compliance with all study assessments and adherence to the protocol schedule of assessment 6. Prior exposure to SPR720. Participants who are unable to comply with the requirements of the study or who in the opinion of the Investigator should not participate in the study are not eligible * Other inclusion and exclusion criteria as per protocol may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nontuberculous mycobacterial pulmonary disease (NTM-PD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Facility
Birmingham, Alabama, 35233, United States
-
Medical Facility
Fresno, California, 93701, United States
-
Medical Facility
Los Angeles, California, 90033, United States
-
Medical Facility
Newport Beach, California, 92663, United States
-
Medical Facility
Northridge, California, 91324, United States
-
Medical Facility
Santa Clarita, California, 91355, United States
-
Medical Facility
Washington D.C., District of Columbia, 20007, United States
-
Medical Facility
Kissimmee, Florida, 34746-4654, United States
-
Medical Facility
Loxahatchee Groves, Florida, 33470, United States
-
Medical Facility
Miami, Florida, 33136, United States
-
Medical Facility
Sebring, Florida, 33870, United States
-
Medical Facility
Tampa, Florida, 33606, United States
-
Medical Facility
Iowa City, Iowa, 52242, United States
-
Medical Facility
Kansas City, Kansas, 66103, United States
-
Medical Facility
New Bedford, Massachusetts, 02740, United States
-
Medical Facility
Rochester, Minnesota, 55905, United States
-
Medical Facility
Lebanon, New Hampshire, 03756, United States
-
Medical Facility
New Hyde Park, New York, 11042, United States
-
Medical Facility
Chapel Hill, North Carolina, 27599, United States
-
Medical Facility
Winston-Salem, North Carolina, 27103, United States
-
Medical Facility
Cleveland, Ohio, 44106, United States
-
Medical Facility
Portland, Oregon, 97239, United States
-
Medical Facility
Pittsburgh, Pennsylvania, 15213, United States
-
Medical Facility
Charleston, South Carolina, 29425, United States
-
Medical Facility
Denison, Texas, 75020, United States
-
Medical Facility
Sherman, Texas, 75090, United States
-
Medical Facility
Tyler, Texas, 75708, United States
-
Medical facility
Atlanta, Georgia, 30342, United States